Research programme: anabolic bone therapeutics - Acceleron

Drug Profile

Research programme: anabolic bone therapeutics - Acceleron

Alternative Names: ACE-05X; ACE-661

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acceleron Pharma
  • Class Proteins
  • Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bone resorption

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-resorption in USA
  • 21 Feb 2008 Acceleron Pharma and Celgene Corporation enter into an option agreement for certain discovery stage bone loss programmes
  • 21 Feb 2008 Early research in Bone regeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top